Indication
Details coming soon
Details coming soon
| Clinical Information | Administration Information |
|---|---|
|
Indication: Adjunct to Type 2 diabetes mellitus Age: Adult |
Dose: Subcutaneous – 0.6 mg Frequency: once daily Duration: 1 week Note: Initial dose is only to decrease gastrointestinal adverse effects and does not provide glycemic control. When initiating, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) to reduce the risk of hypoglycemia. |
|
Indication: Adjunct to Type 2 diabetes mellitus Age: Adult |
Dose: Subcutaneous – 1.2 mg Frequency: once daily Duration: at least 1 week Note: Increase to this dose after 1 week of 0.6 mg/day. |
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Safety and efficacy not established Note: Safety and efficacy not established |
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment |
Dose: Not mentioned Note: No dosage adjustment needed. |
| Drug Name | Risk Factors |
|---|---|
|
Oral Contraceptives
|
Lowered ethinyloestradiol and levonorgestrel Cmax; delayed Tmax
|
|
Insulin secretagogues (e.g. sulfonylurea, meglitinide)
|
Increased risk of hypoglycaemia
|
| Disease Name | Risk Factors |
|---|---|
|
Type 1 diabetes
|
Not effective, inappropriate treatment
|
|
Diabetic ketoacidosis
|
Can worsen condition
|
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.